Name | Type | Description | Interventions |
---|
Sotorasib + trametinib | Experimental | Experimental: Sotorasib + trametinib Dose Exploration and Dose Expansion
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors. | |
Sotorasib + AMG 404 | Experimental | Experimental: Sotorasib + AMG 404 Dose Exploration and Dose Expansion
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors. | |
Sotorasib + RMC-4630 | Experimental | Experimental: Sotorasib + RMC-4630 Dose Exploration and Dose Expansion
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants, with KRAS p.G12C mutant advanced solid tumors. | |
Sotorasib + afatinib | Experimental | Experimental:Sotorasib + afatinib Dose Exploration and Dose Expansion
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced non-small cell lung cancer.
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer. | |
Sotorasib + pembrolizumab | Experimental | Experimental: Sotorasib + pembrolizumab Dose Exploration and Dose Expansion
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer.
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer. | |
Sotorasib + panitumumab +/- FOLFIRI | Experimental | Experimental: Sotorasib + panitumumab +/- FOLFIRI Dose Exploration and Dose Expansion
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer.
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors. | - Sotorasib
- panitumumab
- carboplatin, pemetrexed, docetaxel
|
Sotorasib + atezolizumab | Experimental | Sotorasib + atezolizumab Dose Exploration and Dose Expansion
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer.
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer. | |
Sotorasib + carboplatin, pemetraxed, docetaxel | Experimental | Experimental: Sotorasib + carboplatin, pemetraxed, docetaxel Dose Exploration and Dose Expansion
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer.
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer. | - Sotorasib
- carboplatin, pemetrexed, docetaxel
|
Sotorasib Monotherapy | Experimental | Experimental: Sotorasib only Dose Exploration and Dose Expansion
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer with brain metastases.
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer with brain metastases. | |
Sotorasib + palbociclib | Experimental | Experimental: Sotorasib + palbociclib Dose Exploration and Dose Expansion
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced solid tumor.
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumor. | |
Sotorasib + everolimus | Experimental | Experimental: Sotorasib + everolimus Dose Exploration and Dose Expansion
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced solid tumor.
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumor. | |
Sotorasib + trametinib+ panitumumab | Experimental | Experimental: Sotorasib + trametinib+ panitumumab Dose Exploration and Dose Expansion
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer.
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS P.G12C mutant advanced colorectal cancer. | - Sotorasib
- trametinib
- panitumumab
|
Sotorasib + MVASI® (bevacizumab-awwb)+ FOLFIRI or FOLFOX | Experimental | Experimental: Sotorasib + MVASI® (bevacizumab-awwb)+ FOLFIRI or FOLFOX Dose Exploration and Dose Expansion
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer.
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced colorectal cancer. | - Sotorasib
- carboplatin, pemetrexed, docetaxel
- MVASI® (bevacizumab-awwb)
|